Patents by Inventor Joseph Grudzinski

Joseph Grudzinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
    Publication number: 20230398239
    Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor.
    Type: Application
    Filed: March 13, 2023
    Publication date: December 14, 2023
    Inventors: Jamey Weichert, Paul Sondel, Ravi Patel, Zachary Morris, Peter Carlson, Reinier Hernandez, Joseph Grudzinski
  • Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
    Patent number: 11633506
    Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: April 25, 2023
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jamey Weichert, Paul Sondel, Ravi Patel, Zachary Morris, Peter Carlson, Reinier Hernandez, Joseph Grudzinski
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 11439709
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: September 13, 2022
    Assignee: Cellectar Biosciences, Inc.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles
    Publication number: 20180333498
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Application
    Filed: February 12, 2018
    Publication date: November 22, 2018
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
    Publication number: 20180126012
    Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor.
    Type: Application
    Filed: November 10, 2017
    Publication date: May 10, 2018
    Inventors: Jamey Weichert, Paul Sondel, Ravi Patel, Zachary Morris, Peter Carlson, Reinier Hernandez, Joseph Grudzinski
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 9925269
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: March 27, 2018
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 9480754
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: November 1, 2016
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles
    Publication number: 20160228564
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid ether analogs as cancer-targeting drug vehicles
    Patent number: 9345718
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 24, 2016
    Assignee: CELLECTAR BIOSCIENCES, INC.
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles
    Publication number: 20160136190
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 19, 2016
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle
  • Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles
    Publication number: 20160136290
    Abstract: The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 19, 2016
    Inventors: Jamey P. Weichert, Anatoly Pinchuk, Kevin Kozak, Marc Longino, Joseph Grudzinski, Benjamin Titz, Chorom Pak, Nathan Stehle